Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several ...

This collaboration enables Ontada to deliver access to quality unstructured data four times faster than it did before and provides Ontada's life sciences clients more robust real-world data and ...

NEW YORK, March 18, 2025 /PRNewswire/ — Canopy, the first Continuous Care Platform for oncology, today announced a multi-year partnership with Texas Oncology, one of the nation’s largest ...

BOSTON--(BUSINESS WIRE)--Ontada®, a McKesson business dedicated to oncology real-world data and evidence, clinical education, and point of care technologies, today announced that it is collaborating ...

Please provide your email address to receive an email when new articles are posted on . A viewpoint paper outlined the benefits of a well-coordinated patient-reported outcomes collection system. The ...

The health tech market is projected to grow from $240 billion in 2022 to $1043 billion by 2030. Technologies like EHRs, e-prescribing, and telehealth aim to simplify tasks for providers and patients.

Since 2024, the Sloan Precision Oncology Institute has supported innovative precision oncology research through our research funding awards. To date, ten projects have been funded through our Ignition ...

To develop a technology assessment of chemotherapy sensitivity and resistance assays in order to define the role of these tests in routine oncology practice. The American Society of Clinical Oncology ...

Tampa, Florida, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Inspirata Inc. and FUJIFILM Corporation signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx ® digital pathology technology, ...

McKesson's acquisition of FCS' Core Ventures integrates FCS into The US Oncology Network, expanding its reach to over 700 locations and 1.5 million patients annually. The consolidation trend in ...